Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech Inc. (AIM) has completed its At-The-Market (ATM) facility and closed its Equity Distribution Agreement (EDA). The company asserts it has sufficient funds to support its operational needs and clinical trials for the next 24 months. AIM plans to independently finance key developmental programs in oncology, COVID-19, ME/CFS, and Long COVID, aiming for significant advancements in 2021. CEO Thomas K. Equels highlighted the company's financial stability and commitment to achieving objectives without a renewed ATM facility.
AIM ImmunoTech has partnered with the Centre for Human Drug Research to conduct a clinical study on its Ampligen drug as an intranasal therapy for COVID-19. The study, titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen," will enroll 40 healthy subjects and is fully funded by AIM. Results may provide crucial insights into the potential of Ampligen as a COVID-19 treatment, though future success is uncertain and dependent on many factors.
AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced the postponement of its upcoming investor conference call due to the recent passing of CEO Thomas K. Equels' mother. The company remains committed to its focus on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. The new date for the investor call will be communicated later.
AIM ImmunoTech has initiated the dosing of its first COVID-19 'Long Hauler' patient in the AMP-511 Expanded Access Program (EAP) with Ampligen (rintatolimod). This program addresses chronic post-COVID-19 symptoms. AIM plans to host a conference call on January 12, 2021, to update on this trial and their ongoing advancements. The EAP will enroll up to 100 participants suffering from Chronic Fatigue Syndrome, including 20 Long Haulers. AIM's CEO emphasized the urgency of developing effective therapies for these long-term COVID effects, highlighting Ampligen’s potential.
AIM ImmunoTech Inc. announced that the post-COVID-19 'Long Hauler' segment of its AMP-511 Expanded Access Program received Institutional Review Board approval for public notification of patient enrollment. The trial will include treatments with their drug Ampligen, targeting chronic fatigue symptoms in COVID-19 survivors identified as 'Long Haulers'. Up to 100 participants may be enrolled, with 20 allocated to Long Haulers. The program aims to address a significant public health need as millions face ongoing symptoms of fatigue post-COVID-19.
AIM ImmunoTech has announced the approval of its post-COVID-19 Long Hauler clinical trial for its drug Ampligen. The Institutional Review Board (IRB) has authorized public notification for enrollment, allowing up to 100 participants, including 20 Long Haulers experiencing chronic fatigue post-COVID-19. Ampligen, an immune-system modulator, is already approved for Chronic Fatigue Syndrome in Argentina and is the only late-stage candidate in the U.S. for ME/CFS. AIM aims to address the critical health need for therapies targeting chronic fatigue resulting from COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) received Orphan Drug Designation from the U.S. FDA for its drug Ampligen (rintatolimod), aimed at treating pancreatic cancer. This designation grants seven years of market exclusivity upon approval. Pancreatic cancer is notably lethal, with a five-year survival rate of only 6%. Recent data from a study at Erasmus University Medical Center indicated that patients treated with Ampligen had a median survival rate 200% higher than a historical control group. However, further testing and trials are required to confirm effectiveness.
AIM ImmunoTech Inc. announced that the FDA granted Orphan Drug Designation for its drug Ampligen (rintatolimod) to treat pancreatic cancer, a disease with a low five-year survival rate of just 6%. This designation provides seven years of market exclusivity upon approval. The company also reported statistically significant survival results from a study at Erasmus University, showing a median survival rate approximately 200% higher in patients treated with Ampligen compared to a historical control group. This suggests potential for extended survival rates against the standard care for pancreatic cancer.
AIM ImmunoTech Inc. (NYSE American: AIM) reports progress in developing treatments for COVID-19, with its collaboration in a Phase 1/2a study at Roswell Park Comprehensive Cancer Center for a two-drug regimen involving Ampligen and interferon alpha-2b. The study is underway, with the first patient treated. AIM is also focusing on intranasal prophylaxis for high-risk groups and therapies for COVID-19 Long Haulers. AIM emphasizes the need for early treatments amid vaccine developments from major pharmaceutical firms. The company remains committed to advancing its research efforts.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
